Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Constitutive Androstane Receptor Ligands Modulate the Anti-Tumor Efficacy of Paclitaxel in Non-Small Cell Lung Cancer Cells

Full text
Author(s):
Fukumasu, Heidge [1] ; Rochetti, Arina L. [1] ; Pires, Pedro R. L. [1] ; Silva, Edson R. [1] ; Mesquita, Ligia G. [1] ; Strefezzi, Ricardo F. [1] ; De Carvalho, Daniel D. [2, 3] ; Dagli, Maria L. [4]
Total Authors: 8
Affiliation:
[1] Univ Sao Paulo, Sch Anim Sci & Food Engn, Dept Vet Med, Lab Comparat & Translat Oncol, Pirassununga - Brazil
[2] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Campbell Family Canc Res Inst, Toronto, ON - Canada
[3] Univ Toronto, Dept Med Biophys, Toronto, ON - Canada
[4] Univ Sao Paulo, Sch Vet Med & Anim Sci, Dept Pathol, Lab Expt & Comparat Oncol, Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: PLoS One; v. 9, n. 6 JUN 24 2014.
Web of Science Citations: 6
Abstract

Background: Lung tumors are the leading cause of cancer deaths worldwide and paclitaxel has proven to be useful for patients with lung cancer, however, acquired resistance is a major problem. To overcome this problem, one promising option is the use of Constitutive Androstane Receptor (CAR) ligands in combination with chemotherapeutics against cancer cells. Therefore, we wish to elucidate the effects of CAR ligands on the antineoplastic efficacy of paclitaxel in lung cancer cells. Methodology/Principal Findings: Our results from cell viability assays exposing CAR agonist or inverse-agonist to mouse and human lung cancer cells modulated the antineoplastic effect of paclitaxel. The CAR agonists increased the effect of Paclitaxel in 6 of 7 lung cancer cell lines, whereas the inverse-agonist had no effect on paclitaxel cytotoxicity. Interestingly, the mCAR agonist TCPOBOP enhanced the expression of two tumor suppressor genes, namely WT1 and MGMT, which were additively enhanced in cells treated with CAR agonist in combination with paclitaxel. Also, in silico analysis showed that both paclitaxel and CAR agonist TCPOBOP docked into the mCAR structure but not the inverse agonist androstenol. Paclitaxel per se increases the expression of CAR in cancer cells. At last, we analyzed the expression of CAR in two public independent studies from The Cancer Genome Atlas (TCGA) of Non Small Cell Lung Cancer (NSCLC). CAR is expressed in variable levels in NSCLC samples and no association with overall survival was noted. Conclusions/Significance: Taken together, our results demonstrated that CAR agonists modulate the antineoplastic efficacy of paclitaxel in mouse and human cancer cell lines. This effect was probably related by the enhanced expression of two tumor suppressor genes, viz. WT1 and MGMT. Most of NSCLC cases present CAR gene expression turning it possible to speculate the use of CAR modulation by ligands along with Paclitaxel in NSCLC therapy. (AU)

FAPESP's process: 10/05650-5 - Nutrigenetic evaluation of constitutive androstane receptor (CAR, NR1i3) on feed efficiency in Nelore cattle
Grantee:Heidge Fukumasu
Support Opportunities: Regular Research Grants
FAPESP's process: 09/11081-6 - Characterization of expression and localization of CAR receptor (NR1i3) in NNK [4-(METHYLNITROSAMINE)-1-(3-PIRYDIL)-1-BUTANONE]-induced lung tumors in mice
Grantee:Tássia Sant'Ana Samóra
Support Opportunities: Scholarships in Brazil - Scientific Initiation